Aethlon Medical reports FY2026 net loss $7.2M, cash $5.0M; oncology study enters final cohort

AETHLON MEDICAL INC

Net loss $7.2M vs $13.4M prior year; operating expenses down 21.9% to $7.3M.
Cash $5.0M at March 31; subsequent $1.85M raised via ATM program.
Australian oncology study advanced to Cohort 3; first patient treated in final dosing cohort.
Patents issued in US and Europe for Hemopurifier in long COVID/coronavirus, extending protection to 2040s.
Preclinical studies for rheumatoid arthritis and chronic kidney disease underway.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AETHLON MEDICAL INC reported financial results for the fiscal year ended March 31, 2026.

Period: the fiscal year ended March 31, 2026
Result: reported results

Exact text from the filing

Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment, today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

AETHLON MEDICAL INC filing history →

Source: SEC EDGAR

accession 0001683168-26-004707

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.